查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606317

細胞和基因治療生物製造 CDMO 市場：按組成部分、階段和適應症分類 - 全球預測 2025-2030

Cell & Gene Therapy Biomanufacturing CDMO Market by Component (Cell Therapy, Plasmid DNA, Viral Vector), Phase (Phase 1, Phase 2, Phase 3), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年細胞和基因治療生物製造CDMO市場價值為3.3812億美元，預計2024年將達到4.8547億美元，複合年成長率為32.53%，2030年將達到2.4%，預計將達到2890兆美元。

細胞和基因治療生物製造合約開發和受託製造廠商(CDMO) 是生物製藥行業的重要組成部分，專注於針對遺傳疾病和癌症的高度個人化治療的客製化生產。此細分市場的推動因素包括慢性病的日益普及、CRISPR 等基因編輯技術的進步以及生物技術研發投資的增加。對 CDMO 的需求源於細胞和基因療法生產的複雜性和資源集中性質，這需要專門的設施、技術專長並遵守嚴格的監管標準。這些治療方法的應用多種多樣，包括癌症治療、罕見遺傳疾病和再生醫學，最終用途主要是醫院、研究機構和生物技術公司。主要成長動力包括細胞和基因療法監管核准率的提高、製造流程的技術進步以及公共和私人資金的增加。潛在的商機包括擴大與生物技術公司的夥伴關係，透過自動化和人工智慧提高製造能力，以及擴大生產規模以滿足不斷成長的需求。為企業提供的研究提案包括投資最先進的設備、培養技術純熟勞工以及與研究機構合作持續創新。然而，市場擴張受到高製造成本、治療交付中的物流挑戰以及監管障礙的限制。此外，治療藥物的高成本限制了患者立即獲得治療，而對基因改造的倫理擔憂可能會延遲更廣泛的接受。需要創新的領域包括制定具有成本效益的生產策略、改善供應鏈物流以及發現新的治療應用。對同種異體療法的研究和基因編輯技術精確度的提高有可能簡化生產並降低成本。市場的特點是快速發展，需要敏捷的策略和適應性的經營模式，以利用新趨勢並有效克服現有挑戰。

主要市場統計
基準年[2023] 33812萬美元
預計年份 [2024] 4.8547 億美元
預測年份 [2030] 24.289 億美元
複合年成長率（%） 32.53%

市場動態：快速發展的細胞和基因治療生物製造 CDMO 市場揭示的關鍵市場洞察

細胞和基因療法生物製造 CDMO 市場正在因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 增加細胞工程、基因工程和治療方法的研發活動
    • 治療慢性和遺傳疾病的基因療法的需求不斷成長
    • CDMO 與大公司之間的合作活動增加
  • 市場限制因素
    • CDMO服務成本高
  • 市場機會
    • CDMO引進數位化和人工智慧技術的舉措
    • 生物技術和製藥新興企業的增加
  • 市場挑戰
    • 圍繞基因和細胞研究的複雜法規

波特五力：引領細胞與基因療法生物製造 CDMO 市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對細胞和基因治療生物製造 CDMO 市場的影響

外部宏觀環境因素在塑造細胞和基因治療生物製造 CDMO 市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解細胞和基因治療生物製造 CDMO 市場的競爭狀況

對細胞和基因療法生物製造 CDMO 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位、基質細胞與基因治療生物製造CDMO市場供應商績效評估

FPNV定位矩陣是評估細胞和基因治療生物製造CDMO市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 規劃細胞和基因治療生物製造 CDMO 市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，細胞和基因治療生物製造 CDMO 市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加細胞工程、基因工程和治療方法的研究和開發活動
      • 對治療慢性和遺傳疾病的基因療法的需求日益成長。
      • CDMO 和大公司之間的合作活動增加
    • 抑制因素
      • CDMO服務高成本
    • 機會
      • CDMO引進數位化和人工智慧技術的舉措
      • 生物技術和製藥新興企業的增加
    • 任務
      • 圍繞基因和細胞研究的複雜法規
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 細胞/基因治療生物製造 CDMO 市場：依組成部分

  • 細胞療法
  • 質體DNA
  • 病毒載體

第7章細胞/基因治療生物製造CDMO市場分階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第8章以適應症分類的細胞/基因治療生物製造 CDMO 市場

  • 癌症
  • 心血管疾病
  • 遺傳疾病
  • 感染疾病
  • 神經系統疾病

第9章北美和南美細胞/基因治療生物製造CDMO市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太細胞與基因治療生物製造CDMO市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲細胞和基因治療生物製造CDMO市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AGC Biologics
  • Almac Group
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Catalent Inc.,
  • Charles River Laboratories International Inc.
  • Danaher Corporation
  • Endress+Hauser Group Services AG
  • FUJIFILM Diosynth Biotechnologies
  • GC Corporation
  • General Electric Company
  • Getinge AB
  • Infors AG
  • Lonza Group Ltd
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Patheon Inc.
  • PCI Pharma Services
  • Pfizer CentreOne
  • PIERRE GUERIN
  • Recipharm AB
  • Samsung Biologics
  • Sartorius AG
  • Thermo Fisher Scientific
  • uBriGene
  • WuXi Advanced Therapies
  • WuXi AppTec
Product Code: MRR-5C6F41F5AF94

The Cell & Gene Therapy Biomanufacturing CDMO Market was valued at USD 338.12 million in 2023, expected to reach USD 485.47 million in 2024, and is projected to grow at a CAGR of 32.53%, to USD 2,428.90 million by 2030.

Cell and gene therapy biomanufacturing Contract Development and Manufacturing Organizations (CDMOs) represent a crucial segment in the biopharmaceutical industry, focusing on the bespoke production of advanced, personalized therapies targeting genetic diseases and cancers. This market segment is driven by the increasing prevalence of chronic diseases, advancements in gene editing technologies like CRISPR, and growing investments in biotech research and development. The necessity of CDMOs stems from the complex and resource-intensive nature of cell and gene therapy production, which requires specialized facilities, technical expertise, and compliance with stringent regulatory standards. Applications of these therapies are vast, spanning cancer treatment, rare genetic disorders, and regenerative medicine, with end-use primarily in hospitals, research institutes, and biotech companies. Key growth drivers include the rising approval rates of cell and gene therapies by regulatory bodies, technological advancements in manufacturing processes, and increasing public and private funding. Potential opportunities lie in expanding partnerships with biotech firms, enhancing manufacturing capabilities with automation and AI, and scaling production to meet increasing demand. Recommendations for companies include investing in state-of-the-art facilities, training a skilled workforce, and collaborating with research institutions for continuous innovation. However, market expansion is constrained by high production costs, logistical challenges in therapy delivery, and regulatory barriers. Furthermore, the high cost of therapies limits immediate patient accessibility, while ethical concerns regarding genetic modification may delay broader acceptance. Areas ripe for innovation include developing cost-effective production strategies, improving supply chain logistics, and discovering novel therapeutic applications. Research into allogeneic therapies and improving the precision of gene editing technologies could streamline production and lower costs. The market is characterized by rapid evolution, necessitating agile strategies and adaptive business models to leverage emerging trends and overcome existing challenges effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 338.12 million
Estimated Year [2024] USD 485.47 million
Forecast Year [2030] USD 2,428.90 million
CAGR (%) 32.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Biomanufacturing CDMO Market

The Cell & Gene Therapy Biomanufacturing CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of R&D activities in cellular and genetic engineering and therapies
    • Increasing need for genetic treatments to cure chronic and genetic disorders
    • Rising number of collaborative activities between CDMOs and major players
  • Market Restraints
    • High cost of CDMO services
  • Market Opportunities
    • Efforts by CDMOs to incorporate digitalization and AI technologies
    • Rising number of biotechnology and pharmaceutical startups
  • Market Challenges
    • Complex regulations surrounding genetic and cell research

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Biomanufacturing CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Biomanufacturing CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Biomanufacturing CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Biomanufacturing CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Biomanufacturing CDMO Market

A detailed market share analysis in the Cell & Gene Therapy Biomanufacturing CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Biomanufacturing CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Biomanufacturing CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Biomanufacturing CDMO Market

A strategic analysis of the Cell & Gene Therapy Biomanufacturing CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Biomanufacturing CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Catalent Inc.,, Charles River Laboratories International Inc., Danaher Corporation, Endress+Hauser Group Services AG, FUJIFILM Diosynth Biotechnologies, GC Corporation, General Electric Company, Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Patheon Inc., PCI Pharma Services, Pfizer CentreOne, PIERRE GUERIN, Recipharm AB, Samsung Biologics, Sartorius AG, Thermo Fisher Scientific, uBriGene, WuXi Advanced Therapies, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Biomanufacturing CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Cell Therapy, Plasmid DNA, and Viral Vector.
  • Based on Phase, market is studied across Phase 1, Phase 2, Phase 3, and Phase 4.
  • Based on Indication, market is studied across Cancer, Cardiovascular Disease, Genetic Disorders, Infectious Disease, and Neurological Disorders.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of R&D activities in cellular and genetic engineering and therapies
      • 5.1.1.2. Increasing need for genetic treatments to cure chronic and genetic disorders
      • 5.1.1.3. Rising number of collaborative activities between CDMOs and major players
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of CDMO services
    • 5.1.3. Opportunities
      • 5.1.3.1. Efforts by CDMOs to incorporate digitalization and AI technologies
      • 5.1.3.2. Rising number of biotechnology and pharmaceutical startups
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulations surrounding genetic and cell research
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Biomanufacturing CDMO Market, by Component

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Plasmid DNA
  • 6.4. Viral Vector

7. Cell & Gene Therapy Biomanufacturing CDMO Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase 1
  • 7.3. Phase 2
  • 7.4. Phase 3
  • 7.5. Phase 4

8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Indication

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Disease
  • 8.4. Genetic Disorders
  • 8.5. Infectious Disease
  • 8.6. Neurological Disorders

9. Americas Cell & Gene Therapy Biomanufacturing CDMO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cell & Gene Therapy Biomanufacturing CDMO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cell & Gene Therapy Biomanufacturing CDMO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AGC Biologics
  • 2. Almac Group
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Bio-Techne Corporation
  • 6. Catalent Inc.,
  • 7. Charles River Laboratories International Inc.
  • 8. Danaher Corporation
  • 9. Endress+Hauser Group Services AG
  • 10. FUJIFILM Diosynth Biotechnologies
  • 11. GC Corporation
  • 12. General Electric Company
  • 13. Getinge AB
  • 14. Infors AG
  • 15. Lonza Group Ltd
  • 16. Merck KGaA
  • 17. Miltenyi Biotec B.V. & Co. KG
  • 18. Patheon Inc.
  • 19. PCI Pharma Services
  • 20. Pfizer CentreOne
  • 21. PIERRE GUERIN
  • 22. Recipharm AB
  • 23. Samsung Biologics
  • 24. Sartorius AG
  • 25. Thermo Fisher Scientific
  • 26. uBriGene
  • 27. WuXi Advanced Therapies
  • 28. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023